Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.

Breast Cancer Res Treat

Division of Oncology, Department of Clinical Sciences Lund, Skåne University Hospital, Lund University, 221 85, Lund, Sweden.

Published: November 2022

Purpose: To study the risk of incident breast cancer and subtype-specific breast cancer in relation to excess body weight in a contemporary Swedish prospective cohort study, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA.

Methods: A total of 35,412 postmenopausal women attending mammography and included in the KARMA study provided baseline data on body mass index (BMI) and potential confounders. During eight years of follow-up, 822 incident invasive breast cancer cases were identified.

Results: Women with overweight (BMI ≥ 25-< 30 kg/m) constituting 34% of the study cohort had an increased risk of incident breast cancer with an adjusted Hazard Ratio (HR) 1.19 (95% CI 1.01-1.4). A similar, however, non-significant, association was found for women with obesity (BMI ≥ 30 kg/m) conferring 13% of the cohort, with a HR of 1.19 (95% CI 0.94-1.5). Overweight was associated with risk of node-negative disease (HR 1.29, 95% CI 1.06-1.58), whereas obesity was associated with node-positive disease (HR 1.64, 95% CI 1.09-2.48). Both overweight and obesity were associated with risk of estrogen receptor positive (ER+) disease (HR 1.20, 95% CI 1.00-1.44 and HR 1.33, 95% CI 1.03-1.71, respectively), and low-grade tumors (HR 1.25, 95% CI 1.02-1.54, and HR 1.40, 95% CI 1.05-1.86, respectively). Finally, obesity was associated with ER+HER2 negative disease (HR 1.37, 95% CI 1.05-1.78) and similarly luminal A tumors (HR 1.43, 95% CI 1.02-2.01).

Conclusion: Overweight and obesity are associated with an increased risk of developing breast cancer, specifically ER+, low-grade, and for obesity, node-positive, high-risk breast cancer indicating a further need for risk communication and preventive programs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550786PMC
http://dx.doi.org/10.1007/s10549-022-06664-7DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
breast
5
cancer
5
postmenopausal overweight
4
overweight breast
4
cancer risk
4
risk karma
4
karma cohort
4
cohort purpose
4
purpose study
4

Similar Publications

Background: Intraoperative ultrasound-guided breast-conserving surgery guarantees real-time direct visualization of tumor and resection margins. We compared surgical, oncologic, and cosmetic outcomes between intraoperative ultrasound-guided breast-conserving surgery and traditional (palpation- or wire-guided) surgery across all breast cancer lesion types.

Methods: This prospective observational cohort study was conducted at the Veneto Institute of Oncology between January 2021 and October 2022.

View Article and Find Full Text PDF

Purpose: Clonal hematopoiesis (CH) has been associated with a variety of adverse outcomes, most notably hematologic malignancy and ischemic cardiovascular disease. A series of recent studies also suggest that CH may play a role in the outcomes of patients with solid tumors, including breast cancer. Here, we review the clinical and biological data that underlie potential connections between CH, inflammation, and breast cancer, with a focus on the prevalence and impact of clonal hematopoiesis of indeterminate potential in patients with breast cancer.

View Article and Find Full Text PDF

Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).

View Article and Find Full Text PDF

Anticancer Effects of MAPK6 siRNA-Loaded PLGA Nanoparticles in the Treatment of Breast Cancer.

J Cell Mol Med

January 2025

Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Yildiz Technical University, Istanbul, Turkiye.

siRNA-loaded nanoparticles open new perspectives for cancer treatment. MAPK6 is upregulated in breast cancer and is involved in cell growth, differentiation and cell cycle regulation. Herein, we aimed to investigate the anticancer effects of MAPK6 knockdown by using MAPK6 siRNA-loaded PLGA nanoparticles (siMAPK6-PLGA-NPs) in MCF-7 breast cancer cells.

View Article and Find Full Text PDF

Carcinosarcoma (CS), also known as metaplastic breast carcinoma with mesenchymal differentiation, is one of the five distinct subtypes of metaplastic breast cancer. It is considered as a mixed, biphasic neoplasm consisting of a carcinomatous component combined with a malignant nonepithelial element of mesenchymal origin without an intermediate transition zone. Although cellular origin of this neoplasm remains controversial, most researchers declare that neoplastic cells derive from a cellular structure with potential biphasic differentiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!